Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)

F Roth-Walter; I M Adcock; C Benito-Villalvilla; R Bianchini; L Bjermer; O Boyman; G Caramori; L Cari; K F Chung; Z Diamant; I Eguiluz-Gracia; E F Knol; Aga Kolios; F Levi-Schaffer; G Nocentini; O Palomares; F Redegeld; B Van Esch; C Stellato

doi:10.1111/all.14478

Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)

F Roth-Walter
, I M Adcock
, C Benito-Villalvilla
, R Bianchini
, L Bjermer
, O Boyman
, G Caramori
, L Cari
, K F Chung
, Z Diamant
, I Eguiluz-Gracia
, E F Knol
, Aga Kolios
, F Levi-Schaffer
, G Nocentini
, O Palomares
, F Redegeld
, B Van Esch
, C Stellato^*

^*Corresponding author for this work

Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria.
Cell and Molecular Biology Group, Airways Disease Section, National Heart and Lung Institute, Imperial College London, London, UK AND Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, The University of Newcastle, Newcastle, New South Wales, Australia.
Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.
Department of Respiratory Medicine and Allergology, Lung and Allergy research, Allergy, Asthma and COPD Competence Center, Lund University, Lund, Sweden.
Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Department of Biomedical Sciences, Dentistry and Morphological and Functional Imaging (BIOMORF), Respiratory Medicine Unit, University of Messina, Messina, Italy.
Department of Medicine, Section of Pharmacology, University of Perugia, Perugia Italy.
Experimental Studies Medicine at National Heart & Lung Institute, Imperial College London & Royal Brompton & Harefield NHS Trust, London, UK.
Department of Clinical Pharmacy & Pharmacology, University Groningen, University Medical Center Groningen and QPS-NL, Groningen, Netherlands.
Allergy Unit, Hospital Regional Universitario de Málaga-Instituto de Investigación Biomédica de Málaga (IBIMA)-ARADyAL, Málaga, Spain.
Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, The Netherlands.
Hebrew University of Jerusalem
Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Therapeutic advances using targeted biologicals and small molecule drugs have achieved significant success in the treatment of chronic allergic, autoimmune and inflammatory diseases particularly for some patients with severe, treatment-resistant forms. This has been aided by improved identification of disease phenotypes. Despite these achievements, not all severe forms of chronic inflammatory and autoimmune diseases are successfully targeted, and current treatment options, besides allergen immunotherapy for selected allergic diseases, fail to change the disease course. T cell-based therapies aim to cure diseases through the selective induction of appropriate immune responses following the delivery of engineered, specific cytotoxic or regulatory T cells (Tregs). Adoptive cell therapies (ACT) with genetically engineered T cells have revolutionized the oncology field, bringing curative treatment for leukemia and lymphoma, while therapies exploiting the suppressive functions of Tregs have been developed in non-oncological settings, such as in transplantation and autoimmune diseases. ACT with Tregs are also being considered in non-oncological settings such as cardiovascular disease, obesity and chronic inflammatory disorders. After describing the general features of T cell-based approaches and current applications in autoimmune diseases, this position paper reviews the experimental models testing or supporting T cell-based approaches, especially Treg-based approaches, in severe IgE-mediated responses and chronic respiratory airway diseases, such as severe asthma and COPD. Along with an assessment of challenges and unmet needs facing the application of ACT in these settings, this article underscores the potential of ACT to offer curative options for patients with severe or treatment-resistant forms of these immune-driven disorders.

Original language	English
Pages (from-to)	90-113
Number of pages	24
Journal	Allergy
Volume	76
Issue number	1
DOIs	https://doi.org/10.1111/all.14478
Publication status	Published - Jan 2021

Bibliographical note

Funding Information:
The Task Force was financed by the European Academy for Allergy and Clinical Immunology (EAACI). CS received funding from University of Salerno and Campania Region (Italy); GC received funding by University of Messina, Sicilia Region (Italy), Chiesi, AstraZeneca, and Enfarma; GN received funding by Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR) under grant number 2017MLC3NF_005; FLS received funding of Emalie Gutterman Memorial Endowed Fund (USA), The Aimwell Charitable Trust (UK), the Israel Science Foundation, and the Binational United States‐Israel Research Foundation; IEG received funding from the Instituto de Salud Carlos III of the Spanish Ministry of Economy and Competitiveness (CM17/00140 and RD16/0006/0001); FRW received funding from Biomed Int. R&D Austria; RB received funding from the Austrian Science Fund FWF project SFB F4606‐B28; IMA receives funding from the EPSRC (EP/T003189/1) and the MRC (MR/T010371/1); and OP received funding from MINECO (SAF2014‐52706‐R and SAF2017‐84978‐R).

Funding Information:
The Task Force was financed by the European Academy for Allergy and Clinical Immunology (EAACI). CS received funding from University of Salerno and Campania Region (Italy); GC received funding by University of Messina, Sicilia Region (Italy), Chiesi, AstraZeneca, and Enfarma; GN received funding by Ministero dell'Istruzione, dell'Universit? e della Ricerca (MIUR) under grant number 2017MLC3NF_005; FLS received funding of Emalie Gutterman Memorial Endowed Fund (USA), The Aimwell Charitable Trust (UK), the Israel Science Foundation, and the Binational United States-Israel Research Foundation; IEG received funding from the Instituto de Salud Carlos III of the Spanish Ministry of Economy and Competitiveness (CM17/00140 and RD16/0006/0001); FRW received funding from Biomed Int. R&D Austria; RB received funding from the Austrian Science Fund FWF project SFB F4606-B28; IMA receives funding from the EPSRC (EP/T003189/1) and the MRC (MR/T010371/1); and OP received funding from MINECO (SAF2014-52706-R and SAF2017-84978-R).

Publisher Copyright:
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CAR-Treg cells
adoptive cell therapies
allergy
autoimmunity
immunoregulation

Access to Document

10.1111/all.14478

all.14478Final published version, 1.66 MBLicence: Taverne

Fingerprint

Dive into the research topics of 'Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)'. Together they form a unique fingerprint.

Cite this

Roth-Walter, F., Adcock, I. M., Benito-Villalvilla, C., Bianchini, R., Bjermer, L., Boyman, O., Caramori, G., Cari, L., Chung, K. F., Diamant, Z., Eguiluz-Gracia, I., Knol, E. F., Kolios, A., Levi-Schaffer, F., Nocentini, G., Palomares, O., Redegeld, F., Van Esch, B., & Stellato, C. (2021). Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). Allergy, 76(1), 90-113. https://doi.org/10.1111/all.14478

@article{ba5435524bc14cc1965c5769832d8f8f,

title = "Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)",

abstract = "Therapeutic advances using targeted biologicals and small molecule drugs have achieved significant success in the treatment of chronic allergic, autoimmune and inflammatory diseases particularly for some patients with severe, treatment-resistant forms. This has been aided by improved identification of disease phenotypes. Despite these achievements, not all severe forms of chronic inflammatory and autoimmune diseases are successfully targeted, and current treatment options, besides allergen immunotherapy for selected allergic diseases, fail to change the disease course. T cell-based therapies aim to cure diseases through the selective induction of appropriate immune responses following the delivery of engineered, specific cytotoxic or regulatory T cells (Tregs). Adoptive cell therapies (ACT) with genetically engineered T cells have revolutionized the oncology field, bringing curative treatment for leukemia and lymphoma, while therapies exploiting the suppressive functions of Tregs have been developed in non-oncological settings, such as in transplantation and autoimmune diseases. ACT with Tregs are also being considered in non-oncological settings such as cardiovascular disease, obesity and chronic inflammatory disorders. After describing the general features of T cell-based approaches and current applications in autoimmune diseases, this position paper reviews the experimental models testing or supporting T cell-based approaches, especially Treg-based approaches, in severe IgE-mediated responses and chronic respiratory airway diseases, such as severe asthma and COPD. Along with an assessment of challenges and unmet needs facing the application of ACT in these settings, this article underscores the potential of ACT to offer curative options for patients with severe or treatment-resistant forms of these immune-driven disorders.",

keywords = "CAR-Treg cells, adoptive cell therapies, allergy, autoimmunity, immunoregulation",

author = "F Roth-Walter and Adcock, \{I M\} and C Benito-Villalvilla and R Bianchini and L Bjermer and O Boyman and G Caramori and L Cari and Chung, \{K F\} and Z Diamant and I Eguiluz-Gracia and Knol, \{E F\} and Aga Kolios and F Levi-Schaffer and G Nocentini and O Palomares and F Redegeld and \{Van Esch\}, B and C Stellato",

note = "Funding Information: The Task Force was financed by the European Academy for Allergy and Clinical Immunology (EAACI). CS received funding from University of Salerno and Campania Region (Italy); GC received funding by University of Messina, Sicilia Region (Italy), Chiesi, AstraZeneca, and Enfarma; GN received funding by Ministero dell'Istruzione, dell'Universit{\`a} e della Ricerca (MIUR) under grant number 2017MLC3NF\_005; FLS received funding of Emalie Gutterman Memorial Endowed Fund (USA), The Aimwell Charitable Trust (UK), the Israel Science Foundation, and the Binational United States‐Israel Research Foundation; IEG received funding from the Instituto de Salud Carlos III of the Spanish Ministry of Economy and Competitiveness (CM17/00140 and RD16/0006/0001); FRW received funding from Biomed Int. R\&D Austria; RB received funding from the Austrian Science Fund FWF project SFB F4606‐B28; IMA receives funding from the EPSRC (EP/T003189/1) and the MRC (MR/T010371/1); and OP received funding from MINECO (SAF2014‐52706‐R and SAF2017‐84978‐R). Funding Information: The Task Force was financed by the European Academy for Allergy and Clinical Immunology (EAACI). CS received funding from University of Salerno and Campania Region (Italy); GC received funding by University of Messina, Sicilia Region (Italy), Chiesi, AstraZeneca, and Enfarma; GN received funding by Ministero dell'Istruzione, dell'Universit? e della Ricerca (MIUR) under grant number 2017MLC3NF\_005; FLS received funding of Emalie Gutterman Memorial Endowed Fund (USA), The Aimwell Charitable Trust (UK), the Israel Science Foundation, and the Binational United States-Israel Research Foundation; IEG received funding from the Instituto de Salud Carlos III of the Spanish Ministry of Economy and Competitiveness (CM17/00140 and RD16/0006/0001); FRW received funding from Biomed Int. R\&D Austria; RB received funding from the Austrian Science Fund FWF project SFB F4606-B28; IMA receives funding from the EPSRC (EP/T003189/1) and the MRC (MR/T010371/1); and OP received funding from MINECO (SAF2014-52706-R and SAF2017-84978-R). Publisher Copyright: {\textcopyright} 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.",

year = "2021",

month = jan,

doi = "10.1111/all.14478",

language = "English",

volume = "76",

pages = "90--113",

journal = "Allergy",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

Roth-Walter, F, Adcock, IM, Benito-Villalvilla, C, Bianchini, R, Bjermer, L, Boyman, O, Caramori, G, Cari, L, Chung, KF, Diamant, Z, Eguiluz-Gracia, I, Knol, EF, Kolios, A, Levi-Schaffer, F, Nocentini, G, Palomares, O, Redegeld, F , Van Esch, B & Stellato, C 2021, 'Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)', Allergy, vol. 76, no. 1, pp. 90-113. https://doi.org/10.1111/all.14478

Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). / Roth-Walter, F; Adcock, I M; Benito-Villalvilla, C et al.
In: Allergy, Vol. 76, No. 1, 01.2021, p. 90-113.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Immune modulation via T regulatory cell enhancement

T2 - disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)

AU - Roth-Walter, F

AU - Adcock, I M

AU - Benito-Villalvilla, C

AU - Bianchini, R

AU - Bjermer, L

AU - Boyman, O

AU - Caramori, G

AU - Cari, L

AU - Chung, K F

AU - Diamant, Z

AU - Eguiluz-Gracia, I

AU - Knol, E F

AU - Kolios, Aga

AU - Levi-Schaffer, F

AU - Nocentini, G

AU - Palomares, O

AU - Redegeld, F

AU - Van Esch, B

AU - Stellato, C

N1 - Funding Information: The Task Force was financed by the European Academy for Allergy and Clinical Immunology (EAACI). CS received funding from University of Salerno and Campania Region (Italy); GC received funding by University of Messina, Sicilia Region (Italy), Chiesi, AstraZeneca, and Enfarma; GN received funding by Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR) under grant number 2017MLC3NF_005; FLS received funding of Emalie Gutterman Memorial Endowed Fund (USA), The Aimwell Charitable Trust (UK), the Israel Science Foundation, and the Binational United States‐Israel Research Foundation; IEG received funding from the Instituto de Salud Carlos III of the Spanish Ministry of Economy and Competitiveness (CM17/00140 and RD16/0006/0001); FRW received funding from Biomed Int. R&D Austria; RB received funding from the Austrian Science Fund FWF project SFB F4606‐B28; IMA receives funding from the EPSRC (EP/T003189/1) and the MRC (MR/T010371/1); and OP received funding from MINECO (SAF2014‐52706‐R and SAF2017‐84978‐R). Funding Information: The Task Force was financed by the European Academy for Allergy and Clinical Immunology (EAACI). CS received funding from University of Salerno and Campania Region (Italy); GC received funding by University of Messina, Sicilia Region (Italy), Chiesi, AstraZeneca, and Enfarma; GN received funding by Ministero dell'Istruzione, dell'Universit? e della Ricerca (MIUR) under grant number 2017MLC3NF_005; FLS received funding of Emalie Gutterman Memorial Endowed Fund (USA), The Aimwell Charitable Trust (UK), the Israel Science Foundation, and the Binational United States-Israel Research Foundation; IEG received funding from the Instituto de Salud Carlos III of the Spanish Ministry of Economy and Competitiveness (CM17/00140 and RD16/0006/0001); FRW received funding from Biomed Int. R&D Austria; RB received funding from the Austrian Science Fund FWF project SFB F4606-B28; IMA receives funding from the EPSRC (EP/T003189/1) and the MRC (MR/T010371/1); and OP received funding from MINECO (SAF2014-52706-R and SAF2017-84978-R). Publisher Copyright: © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

PY - 2021/1

Y1 - 2021/1

N2 - Therapeutic advances using targeted biologicals and small molecule drugs have achieved significant success in the treatment of chronic allergic, autoimmune and inflammatory diseases particularly for some patients with severe, treatment-resistant forms. This has been aided by improved identification of disease phenotypes. Despite these achievements, not all severe forms of chronic inflammatory and autoimmune diseases are successfully targeted, and current treatment options, besides allergen immunotherapy for selected allergic diseases, fail to change the disease course. T cell-based therapies aim to cure diseases through the selective induction of appropriate immune responses following the delivery of engineered, specific cytotoxic or regulatory T cells (Tregs). Adoptive cell therapies (ACT) with genetically engineered T cells have revolutionized the oncology field, bringing curative treatment for leukemia and lymphoma, while therapies exploiting the suppressive functions of Tregs have been developed in non-oncological settings, such as in transplantation and autoimmune diseases. ACT with Tregs are also being considered in non-oncological settings such as cardiovascular disease, obesity and chronic inflammatory disorders. After describing the general features of T cell-based approaches and current applications in autoimmune diseases, this position paper reviews the experimental models testing or supporting T cell-based approaches, especially Treg-based approaches, in severe IgE-mediated responses and chronic respiratory airway diseases, such as severe asthma and COPD. Along with an assessment of challenges and unmet needs facing the application of ACT in these settings, this article underscores the potential of ACT to offer curative options for patients with severe or treatment-resistant forms of these immune-driven disorders.

AB - Therapeutic advances using targeted biologicals and small molecule drugs have achieved significant success in the treatment of chronic allergic, autoimmune and inflammatory diseases particularly for some patients with severe, treatment-resistant forms. This has been aided by improved identification of disease phenotypes. Despite these achievements, not all severe forms of chronic inflammatory and autoimmune diseases are successfully targeted, and current treatment options, besides allergen immunotherapy for selected allergic diseases, fail to change the disease course. T cell-based therapies aim to cure diseases through the selective induction of appropriate immune responses following the delivery of engineered, specific cytotoxic or regulatory T cells (Tregs). Adoptive cell therapies (ACT) with genetically engineered T cells have revolutionized the oncology field, bringing curative treatment for leukemia and lymphoma, while therapies exploiting the suppressive functions of Tregs have been developed in non-oncological settings, such as in transplantation and autoimmune diseases. ACT with Tregs are also being considered in non-oncological settings such as cardiovascular disease, obesity and chronic inflammatory disorders. After describing the general features of T cell-based approaches and current applications in autoimmune diseases, this position paper reviews the experimental models testing or supporting T cell-based approaches, especially Treg-based approaches, in severe IgE-mediated responses and chronic respiratory airway diseases, such as severe asthma and COPD. Along with an assessment of challenges and unmet needs facing the application of ACT in these settings, this article underscores the potential of ACT to offer curative options for patients with severe or treatment-resistant forms of these immune-driven disorders.

KW - CAR-Treg cells

KW - adoptive cell therapies

KW - allergy

KW - autoimmunity

KW - immunoregulation

UR - https://www.scopus.com/pages/publications/85098846922

U2 - 10.1111/all.14478

DO - 10.1111/all.14478

M3 - Article

C2 - 32593226

SN - 0105-4538

VL - 76

SP - 90

EP - 113

JO - Allergy

JF - Allergy

IS - 1

ER -

Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, Boyman O et al. Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). Allergy. 2021 Jan;76(1):90-113. doi: 10.1111/all.14478

Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this